WO2000054770A8 - Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis - Google Patents

Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis

Info

Publication number
WO2000054770A8
WO2000054770A8 PCT/US2000/006667 US0006667W WO0054770A8 WO 2000054770 A8 WO2000054770 A8 WO 2000054770A8 US 0006667 W US0006667 W US 0006667W WO 0054770 A8 WO0054770 A8 WO 0054770A8
Authority
WO
WIPO (PCT)
Prior art keywords
homologs
fragments
methods
pharmaceutical compositions
inhibit angiogenesis
Prior art date
Application number
PCT/US2000/006667
Other languages
French (fr)
Other versions
WO2000054770A1 (en
Inventor
Richard M Thorn
Marc E Lanser
Marsha A Moses
Dmitri G Wiederschain
Original Assignee
Boston Life Sciences Inc
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/442,099 external-priority patent/US6465431B1/en
Application filed by Boston Life Sciences Inc, Childrens Medical Center filed Critical Boston Life Sciences Inc
Priority to EP00916329A priority Critical patent/EP1165059A4/en
Priority to CA002367611A priority patent/CA2367611A1/en
Priority to JP2000604846A priority patent/JP2002539161A/en
Priority to AU37449/00A priority patent/AU774596B2/en
Publication of WO2000054770A1 publication Critical patent/WO2000054770A1/en
Publication of WO2000054770A8 publication Critical patent/WO2000054770A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to pharmaceutical compositions comprising therapeutically effective amounts of troponin C, I or T subunits, fragments or homologs for the treatment of diseases or disorders involving abnormal angiogenesis and methods of use thereof.
PCT/US2000/006667 1999-03-15 2000-03-14 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis WO2000054770A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00916329A EP1165059A4 (en) 1999-03-15 2000-03-14 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
CA002367611A CA2367611A1 (en) 1999-03-15 2000-03-14 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
JP2000604846A JP2002539161A (en) 1999-03-15 2000-03-14 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of using them for inhibiting angiogenesis
AU37449/00A AU774596B2 (en) 1999-03-15 2000-03-14 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26827499A 1999-03-15 1999-03-15
US09/268,274 1999-03-15
US09/442,099 1999-11-17
US09/442,099 US6465431B1 (en) 1999-11-17 1999-11-17 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis

Publications (2)

Publication Number Publication Date
WO2000054770A1 WO2000054770A1 (en) 2000-09-21
WO2000054770A8 true WO2000054770A8 (en) 2001-01-11

Family

ID=26952984

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/006667 WO2000054770A1 (en) 1999-03-15 2000-03-14 Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis

Country Status (5)

Country Link
EP (1) EP1165059A4 (en)
JP (1) JP2002539161A (en)
AU (1) AU774596B2 (en)
CA (1) CA2367611A1 (en)
WO (1) WO2000054770A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030898D1 (en) * 2003-04-16 2011-02-17 Tasuku Honjo SCREENING METHOD FOR REMEDIES FOR HEART DISEASE AND MEDICAL COMPOSITION FOR THE TREATMENT OF HEART DISEASE
JP2007526763A (en) * 2004-01-27 2007-09-20 コンピュゲン エルティーディー． Novel nucleotide and amino acid sequences and assays and methods using them in the diagnosis of heart disease
EP2321651B1 (en) 2008-07-23 2017-08-23 F. Hoffmann-La Roche AG Identification of subjects being susceptible to anti-angiogenesis therapy
JP5553547B2 (en) * 2009-07-14 2014-07-16 俊一 梶岡 Troponin-containing pharmaceutical composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837680A (en) * 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis

Also Published As

Publication number Publication date
CA2367611A1 (en) 2000-09-21
JP2002539161A (en) 2002-11-19
EP1165059A1 (en) 2002-01-02
AU774596B2 (en) 2004-07-01
WO2000054770A1 (en) 2000-09-21
AU3744900A (en) 2000-10-04
EP1165059A4 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
AU2275397A (en) Troponin subunits and fragments useful as angiogenesis inhibitors
WO2007064883A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
BR9917038A (en) Compound, pharmaceutical composition, method of modulating chemokine receptor activity, method of treatment or prevention of inflammatory diseases, method of treatment or prevention of asthma and method of treatment or prevention of inflammatory disorders
WO2003000241A3 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
WO2002014311A3 (en) Urea compounds and methods of uses
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
WO2006047516A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
WO2004005279A3 (en) Substituted anthranilic amide derivatives and methods of use
WO2003057666A3 (en) Inhibitors of dipeptidyl peptidase iv
WO2004007457A3 (en) Substituted benzylamine derivatives and methods of use
WO2002017914A8 (en) Fused pyrrolocarbazoles against inflammation
WO2005046603A3 (en) Pyridine compounds
IL162214A0 (en) Pyridine derivatives and pharmaceutical compositions containing the same
WO2001001748A3 (en) Peptide compounds that bind her2
EP1251126A3 (en) Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2005061467A3 (en) Piperazine derivatives as bradykinin antagonists
WO2004045557A3 (en) Novel lapachone compounds and methods of use thereof
MXPA05004621A (en) Anilinopyrazole derivatives useful for the treatment of diabetes.
DK1032556T3 (en) Pharmaceutically active compounds and methods of use
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
ATE365549T1 (en) REMEDIES FOR STRESS-INDUCED DISEASES
WO2004032864A3 (en) X-nitro compounds, pharmaceutical compositions thereof and uses therof
WO2006029487A8 (en) Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 37449/00

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2367611

Country of ref document: CA

Ref country code: CA

Ref document number: 2367611

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 604846

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916329

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000916329

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 37449/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000916329

Country of ref document: EP